A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Hoffmann-La Roche12 enrolled

Overview

This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia. This study consists of two parts: Part 1 - The main study - 16 weeks in total: Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose. Part 2 - Open Label Extension (OLE) - up to an additional 12 months. Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed. Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Beta-Thalassemia

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of beta-thalassemia * Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as Hb concentrations \>7.5 grams per deciliter (g/dL) and \<9.5 g/dL, less than or equal to 4 transfusions of red blood cell units within 1 year prior to study enrollment, and no transfusion within 12 weeks prior to study enrollment * Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more than 80% compliance from expected use of study medication (based on patient diary and study drug accountability; Part 2 only) * A favorable benefit-risk ratio from treatment with bitopertin as assessed by the Investigator (Part 2 only) Exclusion Criteria: * Any history of gene therapy * History of hemolytic anemia except for beta-thalassemia * Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only) * Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment. * Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to enrollment (Part 1 only) * Depression, treatment with anti-depressants, or other psychiatric illnesses and/or drug abuse * Clinically significant/uncontrolled comorbid disease * Pregnant or breastfeeding females * Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or CYP3A4 inducers within 4 weeks prior to study drug * Active hepatitis B or C or known positive human immunodeficiency virus (HIV) test result * Diagnosis of cancer within previous 5 years unless treatment has resulted in complete freedom from disease for at least 2 years * Any major illness within 1 month or febrile illness within 1 week prior to study drug * Pulmonary hypertension requiring oxygen therapy (Part 1 only)

Locations (4)

Centro della Microcitemia e delle Anemie Congenite - Ospedale Galliera; Oncologia /Cardiologia

Genoa, Liguria, Italy

Ospedale Maggiore di Milano; Cardio-Metabolic Diseases

Milan, Lombardy, Italy

Chronic Care Center

Baabda, Lebanon

Siriraj Hospital; Division of Haematology-Oncology

Bangkok Noi, Thailand

Outcomes

Primary Outcomes

Safety Outcome: Percentage of Participants with Adverse Events (AEs) - Part 1 only

Time frame: Baseline, Week 16, up to Week 22

Efficacy Outcome: Change in Total Hemoglobin (Hb) Level from Baseline to End of 16-Week Treatment Period in Part 1

Time frame: Baseline to Week 16

Long-term Safety Outcome : Percentage of Participants with Adverse Events (AEs) - Part 2 only

Time frame: Baseline to 19 Months

Secondary Outcomes

Apparent Clearance of Bitopertin

Time frame: Part 1: 2,12 hours (H) postdose (PD) on Day 1; 0 H predose (PRD) on Day 2; 0H PRD and 3H PD on Days 15,29,57; 0H PRD and 1,4H PD on Day 85; 0H PRD on Day 113; early withdrawal (ED) up to 22 wks. Part 2: 0H PRD and 1,4H PD on Days 183,365; ED up to 65 wks

Volume of Distribution of Bitopertin

Area Under the Concentration-Time Curve (AUC) of Bitopertin within a Dosing Interval

Minimum Observed Concentration (Cmin) of Bitopertin

Time frame: Part 1: Predose (0 H) on Days 2, 15, 29, 57, 85, 113; and at early withdrawal (up to 22 weeks overall). Part 2: Predose (0 H) and postdose (1, 4 H) on Days 183, 365; and at early withdrawal (up to 65 weeks overall)

Maximum Observed Concentration (Cmax) of Bitopertin

Apparent Elimination Half-Life of Bitopertin

Accumulation Ratio of Bitopertin

Change from Baseline in Absolute Reticulocyte Count

Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

Change from Baseline in Serum Lactate Dehydrogenase Level

Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

Change from Baseline in Serum Bilirubin Level

Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

Change from Baseline in Absolute Red Blood Cell Count

Time frame: Part 1: Baseline, Week 16. Part 2: Up to Week 65

Change in Total Hb Level from Baseline to the End of the Treatment Period in Part 2

Time frame: Baseline, 19 Months